Journal Articles (1 ABS 4*, 1 ABS 3*, 2 ABS 2*, 2 ABS 1*)
Health System Sustainability and Resilience: A Preliminary Provision of Measurement through a “Mash-up” Index (with Alistair McGuire, George Wharton, Sian Hodgson, Mireia Jofre-Bonet, and DongLuu Tran), (2025). Health Economics, Policy and Law (forthcoming)
Do R&D tax credits impact pharmaceutical innovation? Evidence from a synthetic control approach (with Edward Oliver and Mireia Jofre-Bonet), (2024). Research Policy. (ABS 4*, FT50)
Retirement and Household Expenditure in Turbulent Times (with Ioannis Laliotis, Mujaheed Shaikh and Charitini Stavropoulou), (2023). Journal of Family and Economic Issues. (ABS 2*)
Pharmaceutical spending and early-stage innovation in EU countries (with Afschin Gandjour), (2022). Industry and Innovation. (ABS 3*)
Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases (with Mikel Berdud, Mireia Jofre-Bonet, and Adrian Towse), (2022). Applied Economics Letters. (ABS 1*)
Public subsidies for R&D and public sector pharmaceutical innovation (2021). Applied Economics. (ABS 2*)
Revisiting the relationship between price regulation and pharmaceutical R&D investment (with Mujaheed Shaikh and Pietro Del Giudice), (2021). Applied Health Economics and Health Policy. (ABS 1*)
A survey analyzing assumptions for rational decision making in health care (with Afschin Gandjour), (2020). Economics Bulletin.
The impact of wealth and income on the depression of older adults across European welfare regimes (with Cleon Tsimbos, and Georgia Verropoulou), (2020). Ageing & Society.
Other
A Spotlight on Haemophilia Therapies (with Nadine Henderson, Matthias Hofer, George Bray, Mikel Berdud and Grace Hampson), (2024). Office of Health Economics (OHE) Contract Research Report.
The dynamics of drug shortages (with Matthew Napier, Amanda Cole, and Graham Cookson), (2024). Office of Health Economics (OHE) Contract Research Report.
Around The World in HTAs: Greece – Late but with an Optimistic Future (with Athanassios Vozikis), (2023). Office of Health Economics (OHE) Blog.
Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment (with Sian Besley, Phill O'Neill, and Martina Garau), (2023). Office of Health Economics (OHE) Contract Research Report.
Healthcare Systems Sustainability and Resilience: Creating an Index (with Sian Besley, Mireia Jofre-Bonet, Alistair McGuire and George Wharton), (2022). Value in Health.
The Basis for a New Framework to Determine the Cost-Effectiveness Threshold (with Mikel Berdud, Chris Sampson, and Chris Skedgel), (2022). Value in Health.
The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics (with Mikel Berdud, Simon Brassel, Adrian Towse, Lotte Steuten, and Isobel Firth) (2022). Office of Health Economics (OHE) Blog.
Building Cost-Effectiveness Thresholds for the Future (with Mikel Berdud, Chris Sampson, and Chris Skedgel), (2022). Value & Outcomes Spotlight.
Product Development Partnerships (PDPs) and Pharmaceutical Innovation (with Mikel Berdud, Mireia Jofre-Bonet, and Adrian Towse, (2022).Value in Health.
How Does Pharmaceutical Spending Drive Innovation in Europe? (with Isobel Firth), (2022). Office of Health Economics (OHE) Blog.
Does Government Funding Increase Public Sector Development of New Medicines? (with Isobel Firth), (2021). Office of Health Economics (OHE) Blog.
Would Waiving COVID-19 Vaccines Patents Save Lives? (with Mikel Berdud, Mireia Jofre-Bonet, and Adrian Towse), (2021) Office of Health Economics (OHE) Blog.
Blockchain technology in the pharmaceutical industry (with M. Schoener, P. Sandner, et al.), (2019). Die Pharmazeutische Industrie: Pharmind.